Julie Hambleton - Net Worth and Insider Trading

Julie Hambleton Net Worth

The estimated net worth of Julie Hambleton is at least $242,651 dollars as of 2024-05-04. Julie Hambleton is the Director of SpringWorks Therapeutics Inc and owns about 4,648 shares of SpringWorks Therapeutics Inc (SWTX) stock worth over $209,671. Julie Hambleton is the Director of IGM Biosciences Inc and owns about 2,000 shares of IGM Biosciences Inc (IGMS) stock worth over $20,140. Julie Hambleton is also the Director of Erasca Inc and owns about 6,000 shares of Erasca Inc (ERAS) stock worth over $12,840. Details can be seen in Julie Hambleton's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Julie Hambleton has not made any transactions after 2023-07-19 and currently still holds the listed stock(s).

Transaction Summary of Julie Hambleton

To

Julie Hambleton Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Julie Hambleton owns 5 companies in total, including SpringWorks Therapeutics Inc (SWTX) , IDEAYA Biosciences Inc (IDYA) , and IGM Biosciences Inc (IGMS) among others .

Click here to see the complete history of Julie Hambleton’s form 4 insider trades.

Insider Ownership Summary of Julie Hambleton

Ticker Comapny Transaction Date Type of Owner
SWTX SpringWorks Therapeutics Inc 2023-07-19 director
IDYA IDEAYA Biosciences Inc 2019-05-22 SVP & Chief Medical Officer
IGMS IGM Biosciences Inc 2021-08-09 director
2015-11-11 EVP & Chief Medical Officer
2021-07-20 director

Julie Hambleton Latest Holdings Summary

Julie Hambleton currently owns a total of 3 stocks. Among these stocks, Julie Hambleton owns 4,648 shares of SpringWorks Therapeutics Inc (SWTX) as of July 19, 2023, with a value of $209,671 and a weighting of 86.41%. Julie Hambleton owns 2,000 shares of IGM Biosciences Inc (IGMS) as of August 9, 2021, with a value of $20,140 and a weighting of 8.3%. Julie Hambleton also owns 6,000 shares of Erasca Inc (ERAS) as of July 20, 2021, with a value of $12,840 and a weighting of 5.29%.

Latest Holdings of Julie Hambleton

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SWTX SpringWorks Therapeutics Inc 2023-07-19 4,648 45.11 209,671
IGMS IGM Biosciences Inc 2021-08-09 2,000 10.07 20,140
ERAS Erasca Inc 2021-07-20 6,000 2.14 12,840

Holding Weightings of Julie Hambleton


Julie Hambleton Form 4 Trading Tracker

According to the SEC Form 4 filings, Julie Hambleton has made a total of 2 transactions in SpringWorks Therapeutics Inc (SWTX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in SpringWorks Therapeutics Inc is the sale of 2,418 shares on July 19, 2023, which brought Julie Hambleton around $70,872.

According to the SEC Form 4 filings, Julie Hambleton has made a total of 2 transactions in IGM Biosciences Inc (IGMS) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in IGM Biosciences Inc is the sale of 1,000 shares on August 9, 2021, which brought Julie Hambleton around $80,000.

According to the SEC Form 4 filings, Julie Hambleton has made a total of 1 transactions in Erasca Inc (ERAS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Erasca Inc is the acquisition of 6,000 shares on July 20, 2021, which cost Julie Hambleton around $96,000.

Insider Trading History of Julie Hambleton

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Julie Hambleton Trading Performance

GuruFocus tracks the stock performance after each of Julie Hambleton's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Julie Hambleton is 20.84%. GuruFocus also compares Julie Hambleton's trading performance to market benchmark return within the same time period. The performance of stocks bought by Julie Hambleton within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Julie Hambleton's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Julie Hambleton

Average Return

Average return per transaction

Outperforming Transactions

1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -6.38
Relative Return to S&P 500(%) -7.41

Julie Hambleton Ownership Network

Ownership Network List of Julie Hambleton

No Data

Ownership Network Relation of Julie Hambleton


Julie Hambleton Owned Company Details

What does SpringWorks Therapeutics Inc do?

Who are the key executives at SpringWorks Therapeutics Inc?

Julie Hambleton is the director of SpringWorks Therapeutics Inc. Other key executives at SpringWorks Therapeutics Inc include Chief People Officer Daniel Pichl , Chief Commercial Officer Bhavesh Ashar , and Chief Scientific Officer Tai-an Lin .

SpringWorks Therapeutics Inc (SWTX) Insider Trades Summary

Over the past 18 months, Julie Hambleton made 2 insider transaction in SpringWorks Therapeutics Inc (SWTX) with a net sale of 4,818. Other recent insider transactions involving SpringWorks Therapeutics Inc (SWTX) include a net sale of 42,039 shares made by Daniel Pichl , a net sale of 1,750,000 shares made by Jeffrey Lawrence Schwartz , and a net sale of 8,056 shares made by Bhavesh Ashar .

In summary, during the past 3 months, insiders sold 23,056 shares of SpringWorks Therapeutics Inc (SWTX) in total and bought 0 shares, with a net sale of 23,056 shares. During the past 18 months, 1,804,913 shares of SpringWorks Therapeutics Inc (SWTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,804,913 shares.

SpringWorks Therapeutics Inc (SWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

SpringWorks Therapeutics Inc Insider Transactions

No Available Data

Julie Hambleton Mailing Address

Above is the net worth, insider trading, and ownership report for Julie Hambleton. You might contact Julie Hambleton via mailing address: C/o Five Prime Therapeutics, Inc., Two Corporate Drive, South San Francisco Ca 94080.

Discussions on Julie Hambleton

No discussions yet.